Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Scientific Title Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects with Type 2 Diabetes Trial IDs and acronym(s) Novo Nordisk Trial ID NN9924-3991 Clinical Trials.gov Registration NCT01686945 Other Identifier(s) EudraCT Number: 2012-000361-20 Other Identifier: U1111-1127-4408 Condition Diabetes Diabetes Mellitus, Type 2 Healthy Trial dates Start date: 19.Sep.2012 Primary completion date: 08.Apr.2013 Completion date: 08.Apr.2013 Trial phase Phase 1 Treatment semaglutide placebo Arm Information with Assigned Treatment No
A legitimate pharmacy can still have shipping problems
This means compounding pharmacies, which create customized versions, must stop by April 22, 2025, for state-licensed (503A) and May 22, 2025, for outsourcing facilities (503B), unless a court rules otherwise
Novo Nordisk Patient Assistance Program Novo Nordisk offers a patient assistance program that provides Ozempic and Rybelsus at no cost to patients who meet eligibility criteria
Not suitable for individuals with hypersensitivity to any ingredients
